Phase 3 Study of Daily Vortioxetine Treatment in Japanese Teens Aged 12 to 17 With Major Depressive Disorder

What this Trial Is About

Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg per day, works compared to a placebo to treat depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study focuses on assessing both the effectiveness and side effects of vortioxetine in this young population. Participants will take the study drug orally once daily for 14 weeks. The initial dose of vortioxetine starts at 10 mg per day and may be increased to 20 mg per day based on the study plan. Some participants will receive vortioxetine while others will receive a placebo, and the trial is randomized and double-blind to fairly compare outcomes. During the approximately 20-week study, participants will first spend up to 2 weeks screening for eligibility, then take vortioxetine or placebo for 14 weeks, followed by a 4-week period to monitor any side effects after treatment ends. Participants will visit their clinic 13 times for assessments, which include rating scales for depression symptoms and other health evaluations. Researchers will monitor changes in depression severity using tools like the Children Depression Rating Scale and assess safety through clinical observations and tests.

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder